Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
6.75
+0.48 (7.66%)
At close: Feb 21, 2025, 4:00 PM
6.42
-0.33 (-4.91%)
After-hours: Feb 21, 2025, 4:17 PM EST
Tenax Therapeutics Employees
As of December 31, 2023, Tenax Therapeutics had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 2 or -25.00% compared to the previous year.
Employees
6
Change (1Y)
-2
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,426,764
Market Cap
23.01M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
TENX News
- 22 days ago - Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 3 months ago - Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript) - Seeking Alpha
- 3 months ago - Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 4 months ago - Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 7 months ago - Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement - GlobeNewsWire
- 10 months ago - Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 10 months ago - Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - GlobeNewsWire
- 11 months ago - Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” - GlobeNewsWire